SCHEMBL6793972

SCHEMBL6793972

CCc1ccc(-c2ccccc2C(=O)Nc2ccc(N)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.59
NPC1 O15118 4/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
ALDH1A1 P00352 2/20 0.59
MAPT P10636 2/20 0.56
CHRNB2 P17787 1/20 0.56
CHRNB4 P30926 1/20 0.56
CHRNA3 P32297 1/20 0.56
CHRNA4 P43681 1/20 0.56
POLB P06746 1/20 0.53
GAA P10253 1/20 0.53
NR1H4 Q96RI1 1/20 0.48
KMT2A Q03164 2/20 0.48
MAOB P27338 2/20 0.47
MAOA P21397 1/20 0.47
CFTR P13569 1/20 0.47
MEN1 O00255 1/20 0.47
KLF5 Q13887 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TP53 P04637 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7863451 0.84 CHRNB2 (0.78) ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL7084141 0.84 GAA (0.57) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
Hydrochloric Acid SCHEMBL6801121 0.84 CHRNB2 (0.59) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL6795828 0.83 CHRNB2 (0.57) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL28583907 0.82 CHRNB2 (0.50) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL6795356 0.81 CHRNB2 (0.55) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL6792277 0.80 NPC1 (0.46) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL6791178 0.79 PTGS1 (0.67) RAB9ANPC1SMN1; SMN2ALDH1A1CHRNB2
SCHEMBL6795548 0.79 ADRB3 (0.51) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL6795340 0.78 RAB9A (0.53) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 RAB9A 3707/4885NPC1 64/4885SMN1; SMN2 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.